Summary
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the cause of the ongoing worldwide epidemic of Coronavirus Disease 2019 (COVID-19) in China and worldwide. However, there were few studies about the effects of SARS-CoV-2 infection on pregnant women.
Methods In this retrospective cohort study, we enrolled 31 pregnant women and 35 non-pregnant women from Jan 28 to Feb 28, 2020 to evaluate the effects of SARS-CoV-2 infection during pregnancy. Inflammatory indices were used to assess the severity of COVID-19. Evidence of vertical transmission was determined by laboratory confirmation of SARS-CoV-2 in amniotic fluid, placenta, neonatal throat and anal swab and breastmilk samples.
Findings Compared with non-pregnant women, pregnant women had a significantly lower proportion of fever (54·8% vs. 87·5%, p= 0.006), a shorter average interval from onset to hospitalization (7·80 ±7·0d vs. 13·2 ± 8·2d, p= 0.005), and a higher proportion of severe or critical COVID-19 (32·3% vs. 11·4%, p=0.039). Neutrophil-to-lymphocyte ratio (NLR) and systematic immune-inflammation-based prognostic index (SII) were significantly higher on admission in severe/critical pneumonia group than moderate pneumonia group. We could not detect the presence of SARS-CoV-2 by RT-PCR in amniotic fluid, placenta, neonatal throat and anal swab and breastmilk samples.
Interpretation The clinical symptoms of COVID-19 in pregnant women were insidious and atypical, compared with those in non-pregnant patients. SII and NLR could be a useful marker to evaluate the severity of COVID-19. There was no evidence of vertical transmission during pregnancy with SARS-CoV-2 infection.
Funding National Natural Science Foundation of China and Research Funds for the Central Universities.
Evidence before this study We searched PubMed, Embase and Web of science for articles published up to March 1st, 2020, using the keywords (“novel coronavirus” OR “2019 novel coronavirus” OR “2019-nCoV” OR COVID-19 OR SARS-CoV-2) AND (pregnancy OR “maternal infection” OR “fetal infection”) AND “Cohort studies”.
We identified no published cohort studies on pregnant women with the 2019 novel coronavirus disease (COVID-19) infection.
Added value of this study For this retrospective cohort study, we reviewed clinical records, laboratory findings, and chest CT scans from 31 pregnant women and 35 non-pregnant women from Jan 28 to Feb 28, 2020 to evaluate the effects of SARS-CoV-2 infection during pregnancy. Inflammatory indices were used to assess the severity of COVID-19. Evidence of vertical transmission was determined by laboratory confirmation of SARS-CoV-2 in amniotic fluid, placenta, neonatal throat and anal swab and breastmilk samples. Compared with non-pregnant women, pregnant women had a significantly lower proportion of fever (54·8% vs. 87·5%, p= 0.006), a shorter average interval from onset to hospitalization (7·80 ±7·0d vs. 13·2 ± 8·2d, p= 0.005), and a higher proportion of severe or critical COVID-19 (32·3% vs. 11·4%, p=0.039). Neutrophil-to-lymphocyte ratio (NLR) and systematic immune-inflammation-based prognostic index (SII) were significantly higher on admission in severe/critical pneumonia group than moderate pneumonia group. Amniotic fluid, placenta, neonatal throat and anal swab and breastmilk samples were tested for SARS-CoV-2 by RT-PCR and all results were negative.
Implications of all the available evidence The clinical symptoms of COVID-19 in pregnant women were insidious and atypical, compared with those in non-pregnant patients. SII and NLR could be a useful marker to evaluate the severity of COVID-19. There was no evidence of vertical transmission during pregnancy with SARS-CoV-2 infection.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
None
Funding Statement
This study was supported by grants from the General Program the National Natural Science Foundation of China (81874138) and Research Funds for the Central Universities (2020kfyXGYJ008).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Shi-Huan Yu yushihuan2000{at}126.com, Hui Chen chinachen67{at}hust.edu.cn, David Baud David.Baud{at}chuv.ch, Xiang Chen chenxiangck{at}126.com
Data Availability
All data referred to in the manuscript,
